Diagnostics company Immunovia (Nasdaq Stockholm: IMMNOV) reported on Monday that it is continuing to commercialise its IMMray PanCan-d test in the US with the appointment of a new national sales director by its US subsidiary, Immunovia Inc.
The company's IMMray PanCan-d test is the world's first blood test dedicated to the early detection of pancreatic cancer.
Commercialization of IMMray PanCan-d started in August 2021 in the US. The test is offered as a laboratory developed test (LDT) exclusively through Immunovia Inc.
Immunovia added that Jon Hager starts in his position of national sales director on 5 December 2022.
Hager worked at Myriad Genetics where he was a core member of the team that launched hereditary cancer testing to gynecologists.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval